If you are asking what is MOTS-c, the short answer is that it is a small mitochondrial-derived peptide (MDP) that scientists have studied as a signaling molecule linking mitochondrial status to whole-cell and whole-body metabolism. First described in 2015, MOTS-c has become a focal point in laboratory research on energy metabolism, cellular stress responses, and biological aging. This overview summarizes what peer-reviewed and preclinical studies have investigated, framed strictly for scientific and educational understanding rather than any applied use.
What Is MOTS-c at the Molecular Level?
MOTS-c stands for “mitochondrial open reading frame of the 12S rRNA type-c.” It is a 16-amino-acid peptide encoded not by the nuclear genome but by a short open reading frame (sORF) within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). This makes it one of a small family of mitochondrial-derived peptides; the others identified to date are humanin and the small humanin-like peptides (SHLP 1–6). The original characterization of MOTS-c was published by Lee and colleagues in Cell Metabolism, which proposed that mitochondria may act not only as metabolic organelles but also as a source of signaling peptides encoded within their own genome.
Because it is encoded in mitochondrial DNA, MOTS-c is of particular interest to researchers studying “mitonuclear communication” — the idea that the two genomes a cell carries can regulate one another. Reviews of the mitochondrial-derived peptide family describe these molecules as sensitive to metabolic state, with circulating levels reported to vary across conditions such as obesity, diabetes, and aging in the models examined.
How Researchers Describe Its Proposed Mechanism
Mechanistic studies in cell and animal models have examined how MOTS-c may exert its effects. The most frequently cited pathway involves the folate cycle and de novo purine biosynthesis, whose inhibition is proposed to shift the cellular AICAR balance and activate AMP-activated protein kinase (AMPK) — a central sensor of cellular energy status. Skeletal muscle has been identified in these studies as an apparent primary target tissue.
A separate line of work reported that, under metabolic stress such as glucose restriction, MOTS-c can translocate to the cell nucleus and interact with stress-responsive transcription factors, including NRF2 (NFE2L2), influencing the expression of genes carrying antioxidant response elements. Researchers have framed this as evidence that a mitochondrially encoded peptide can help coordinate a broad nuclear stress-adaptation program. It is important to note that these are proposed mechanisms characterized in laboratory systems, not established clinical effects.
What Metabolism Research Has Investigated
Much of the early MOTS-c literature focused on metabolic endpoints in rodent models. In the foundational studies, administration of the peptide in mice was reported to influence insulin sensitivity and to reduce features associated with age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity. Metabolomic analyses in diet-induced obese mice have examined associated changes in plasma lipid and related metabolite pathways. Additional preclinical work has explored MOTS-c in a mouse model of gestational diabetes, where investigators looked at markers of glucose handling and pancreatic beta-cell stress. Across this body of work, the peptide is often discussed as an “exercise mimetic” candidate in research contexts, though the evidence remains preclinical and any translation to humans is unestablished.
MOTS-c, Exercise, and Aging Research
One reason MOTS-c draws attention in aging science is its reported connection to physical activity. A 2021 Nature Communications study found that exercise induced endogenous MOTS-c expression in skeletal muscle and in circulation in humans, and that intermittent MOTS-c administration was associated with measures of physical capacity across young, middle-aged, and old mice. The authors positioned these findings within a broader hypothesis that genes in both the mitochondrial and nuclear genomes participate in regulating age-related physiological decline. As with the metabolic literature, these are observations from experimental models and small human sampling of a naturally occurring peptide, not evidence of any intervention outcome.
Other Areas Under Preclinical Study
Beyond metabolism and aging, exploratory preclinical studies have examined MOTS-c in contexts such as inflammation and tissue-injury models. For example, one rodent and cell study investigated whether the peptide influenced ferroptosis and lung injury following myocardial ischemia-reperfusion, reporting associations with a PPARγ signaling pathway. These represent early-stage, single-study observations that would require substantial independent replication before any conclusions could be drawn.
Where the Evidence Currently Stands
Taken together, the published literature characterizes MOTS-c as a biologically interesting mitochondrial-derived peptide with reproducible signaling activity in cell and animal systems and measurable expression changes in humans in response to exercise. However, the evidence base is still weighted heavily toward preclinical models, mechanistic experiments, and review articles. Rigorous, controlled human studies evaluating defined outcomes are limited, and the field itself frames MOTS-c as a subject of ongoing investigation rather than a settled topic. For anyone seeking to understand the science, the responsible reading is that MOTS-c is a promising research molecule whose mechanisms are partly mapped and whose broader significance remains an open scientific question.
References
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. doi:10.1016/j.cmet.2015.02.009
- Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology & Medicine. 2016. doi:10.1016/j.freeradbiomed.2016.05.015
- Kim KH, et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018. doi:10.1016/j.cmet.2018.06.008
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. doi:10.1038/s41467-020-20790-0
- Merry TL, et al. Mitochondrial-derived peptides in energy metabolism. American Journal of Physiology-Endocrinology and Metabolism. 2020. View via Consensus
- Yin Y, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacological Research. 2021. doi:10.1016/j.phrs.2021.105987
- Lu P, et al. The mitochondrial-derived peptide MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPARγ signaling. European Journal of Pharmacology. 2023. doi:10.1016/j.ejphar.2023.175835
- Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023. doi:10.3389/fendo.2023.1120533
Research Use Only. The information above is provided solely for educational and scientific reference. MOTS-c and related compounds discussed here are intended for laboratory research use only and are not drugs, dietary supplements, or products for human or veterinary use, diagnosis, treatment, or consumption. Nothing in this article constitutes medical advice or a health claim.